Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

5.84
+0.04000.69%
Post-market: 5.71-0.1300-2.23%17:07 EST
Volume:1.27M
Turnover:7.46M
Market Cap:316.44M
PE:-1.47
High:6.10
Open:5.65
Low:5.61
Close:5.80
Loading ...

DEXIS Reflects on a Year of Innovation and Unveils Exciting Plans for 2025

ACCESS Newswire
·
03 Feb

Emergent Biosolutions Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Jan

BRIEF-Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Reuters
·
16 Jan

Emergent BioSolutions Inc - First Interim Analysis of Mosa Trial Expected by End of Q1 2025

THOMSON REUTERS
·
16 Jan

Enrollment Starts in Africa Cdc-Led Mpox Therapeutic Study (Mosa)

THOMSON REUTERS
·
16 Jan

Emergent BioSolutions Shares up 4.3% on Gaining Commercial Rights for Hikma's Opioid Overdose Treatment

THOMSON REUTERS
·
14 Jan

BUZZ-Emergent up on gaining commercial rights for Hikma's opioid overdose treatment

Reuters
·
14 Jan

Emergent BioSolutions Obtains Commercial Rights to Kloxxado Nasal Spray

MT Newswires Live
·
14 Jan

Emergent BioSolutions, Hikma enter partnership for sale of Kloxxado nasal spray

TIPRANKS
·
14 Jan

Emergent BioSolutions gains exclusive commercial rights to KLOXXADO

TIPRANKS
·
14 Jan

Emergent BioSolutions: Hikma Will Continue to Manufacture Kloxxado Nasal Spray 8 Mg to Maintain Distribution and Availability

THOMSON REUTERS
·
14 Jan

Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals

THOMSON REUTERS
·
14 Jan

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GlobeNewswire
·
14 Jan

Emergent Gets Contract Option With BARDA for Ebola Treatment

MT Newswires Live
·
14 Jan

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With Barda on Ebanga™ (Ansuvimab-Zykl) Treatment for Ebola

THOMSON REUTERS
·
13 Jan

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

GlobeNewswire
·
13 Jan